Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 13/20 | 0.58 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.58 |
| ▸ | SMPD1 | P17405 | 5/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.52 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4638947 | 1.00 | FDPS (0.58) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL60846 | 1.00 | FDPS (0.58) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL2695072 | 1.00 | FDPS (0.58) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL1044717 | 1.00 | FDPS (0.58) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL62052 | 1.00 | FDPS (0.58) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL418810 | 1.00 | FDPS (0.58) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL2693656 | 1.00 | FDPS (0.58) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL632447 | 1.00 | FDPS (0.58) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL905578 | 1.00 | FDPS (0.58) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL60424 | 1.00 | FDPS (0.58) | FDPSGGPS1SMPD1LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6506393-B2 | Administering phosphocholine compound; leishmaniasis treatment | ZENTARIS AG (DE) | 2003-01-14 | — | — | US | disclosed |
| US-20010008885-A1 | Methods of treating protozoal diseases | MAX-PLANCK-GESSELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. | 2001-07-19 | — | — | US | disclosed |
| US-6254879-B1 | QUATERNARIUMAMINOETHYLPHOSPHATES | Max-Planck-Gessellschaft zun Förderung der Wissenschaften e.V. (DE) | 2001-07-03 | — | — | US | disclosed |
| EP-0534445-B1 | Process for the preparation of a medicament for oral or topical administration in the treatment of leishmaniasis | MAX PLANCK GESELLSCHAFT (DE) | 1999-03-24 | — | — | EP | disclosed |
| EP-0534445-A1 | Process for the preparation of a medicament for oral or topical administration in the treatment of leishmaniasis | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1993-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008885-A1 | Methods of treating protozoal diseases | HRH2, HRH1, HRH4 | FDPS 1988/4885GGPS1 732/4885SMPD1 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.